Drug Target Commons 2.0 : a community platform for systematic analysis of drug target interaction profiles

Show full item record



Permalink

http://hdl.handle.net/10138/246857

Citation

Tanoli , Z , Alam , Z , Vähä-Koskela , M , Ravikumar , B , Malyutina , A , Jaiswal , A , Tang , J , Wennerberg , K & Aittokallio , T 2018 , ' Drug Target Commons 2.0 : a community platform for systematic analysis of drug target interaction profiles ' , Database-The journal of biological databases and curation . https://doi.org/10.1093/database/bay083

Title: Drug Target Commons 2.0 : a community platform for systematic analysis of drug target interaction profiles
Author: Tanoli, ZiaurRehman; Alam, Zaid; Vähä-Koskela, Markus; Ravikumar, Balaguru; Malyutina, Alina; Jaiswal, Alok; Tang, Jing; Wennerberg, Krister; Aittokallio, Tero
Contributor: University of Helsinki, Institute for Molecular Medicine Finland
University of Helsinki, Institute for Molecular Medicine Finland
University of Helsinki, Institute for Molecular Medicine Finland
University of Helsinki, Institute for Molecular Medicine Finland
University of Helsinki, Institute for Molecular Medicine Finland
University of Helsinki, Institute for Molecular Medicine Finland
University of Helsinki, Institute for Molecular Medicine Finland
University of Helsinki, Institute for Molecular Medicine Finland
Date: 2018-09-13
Language: eng
Number of pages: 13
Belongs to series: Database-The journal of biological databases and curation
ISSN: 1758-0463
URI: http://hdl.handle.net/10138/246857
Abstract: Drug Target Commons (DTC) is a web platform (database with user interface) for community-driven bioactivity data integration and standardization for comprehensive mapping, reuse and analysis of compound-target interaction profiles. End users can search, upload, edit, annotate and export expert-curated bioactivity data for further analysis, using an application programmable interface, database dump or tab-delimited text download options. To guide chemical biology and drug-repurposing applications, DTC version 2.0 includes updated clinical development information for the compounds and target gene-disease associations, as well as cancer-type indications for mutant protein targets, which are critical for precision oncology developments.
Subject: ACUTE MYELOID-LEUKEMIA
METASTATIC MELANOMA
THERAPEUTIC TARGET
IMATINIB MESYLATE
DISCOVERY
KIT
INFORMATION
SORAFENIB
RESOURCE
MUTATION
3111 Biomedicine
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
bay083.pdf 15.32Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record